Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://www.24-7pressrelease.com/press-release/489820/manhattan-biosolutions-announces-grant-award-from-the-university-at-buffalo-center-for-advanced-technology-in-big-data-and-health-sciences Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, […]

https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]

New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]